



Vaccine Development Needs for Marburg Virus and Sudan Ebolavirus: Leveraging Lessons Learned from the Zaire Ebolavirus

Guest Editors:

Dr. Daniel Wolfe

Dr. Kimberly L. Taylor

Dr. Lawrence A. Wolfrain

Dr. Clint Florence

Deadline for manuscript
submissions:

closed (30 June 2022)

Message from the Guest Editors

In this Special Issue, we aim to cover lessons learned from the Zaire ebolavirus vaccine development, and how this can/will be applied to vaccine development for Sudan ebolavirus and Marburg virus. Topics will include perspectives from the USG and product developers on the development of Zaire ebolavirus vaccines, challenges and lessons learned, regulatory strategies, and updates of licensed or lead candidates. Other topics will include the development of standardized tools, such as available immunological assays and animal models, and clinical trial network operations during outbreaks. The goal is to provide an overview of the current status of Marburg virus and Sudan ebolavirus vaccines and some of the key enabling technologies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)